JP Morgan Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has downgraded Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowered the price target from $18 to $12.
July 25, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has downgraded Sage Therapeutics from Overweight to Neutral and reduced the price target from $18 to $12.
The downgrade from Overweight to Neutral and the significant reduction in the price target from $18 to $12 by JP Morgan is likely to negatively impact investor sentiment and the stock price of Sage Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100